KERENDIA®

Drug Information Related Patent

Hold Company

BAYER HLTHCARE

Learn More

Dosage and Administration

TABLET;ORAL

Specification

10MG; 20MG

Indication

KERENDIA® reduces the risk for sustained eGFR decline, end-stage renal disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type II diabetes mellitus (T2D).

Use

Instructions for Use

API

FINERENONE

API Structure

We Supply

FINERENONE

Note:

In-house Standard
Facility GMP
DMF/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8436180	2029/4/12

API Patent

Patent No	Expiration Date
8436180	2029/4/12

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION